Viking Therapeutics announced its financial results for the second quarter and six months ended June 30, 2025, on July 23, 2025. For Q2 2025, the company reported a net loss of $65.6 million, or $0.58 per share, compared to a net loss of $22.3 million, or $0.20 per share, in the corresponding period of 2024. The net loss for the first six months of 2025 was $111.2 million, or $0.99 per share, compared to $49.6 million, or $0.46 per share, in 2024.
Research and development expenses for the second quarter significantly increased to $60.2 million from $23.8 million year-over-year. This rise was primarily due to increased spending on clinical studies, manufacturing for drug candidates, and preclinical studies. General and administrative expenses also grew to $14.4 million from $10.3 million, reflecting the company's accelerated development activities.
As of June 30, 2025, Viking held cash, cash equivalents, and short-term investments of $808 million. This strong cash position provides the necessary runway to support the advancement of VK2735 through Phase 3 clinical trials, in addition to supporting further progress with other key development programs, despite the increased operating losses.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.